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ABSTRACT:  
Hepatitis B infection is caused by the hepatitis B virus (HBV). A double-stranded virus of the hepadnaviridae family. It infects the 
liver, causing hepatocellular necrosis and inflammation. HBV infection can be either acute or chronic, and the associated illness 
ranges in severity from asymptomatic to symptomatic, progressive disease. Over two billion people are known to be infected with 
Hepatitis B virus. Hepatitis B disease is ranked among the ten top killer diseases, with over a million deaths recorded annually from 
chronic HBV infection and its complications: cirrhosis or primary liver cancer. Liver injury occurs through immune-mediated killing 
of infected liver cells. Hepatitis B disease has huge health, mortality and economic burden. This review was aimed at contributing 
to global knowledge on Hepatitis B infection with the objectives of controlling its spread through prevention and vaccination. The 
review was on the burden and epidemiology of HBV, it’s Pathogenesis, Transmission modes, Signs and symptoms, Risk factors for 
Hepatitis B, Diagnosis, Drugs approved for the treatment of chronic hepatitis B and prevention of HBV infection. This review noted 
that HBV vaccination is very effective and remains the best way to prevent Hepatitis B infection. Vaccination should be administered 
to everyone, but especially those who are at risk. Infants should be vaccinated within 24 hours of delivery. The review noted that 
avoiding risky behaviours through the practice of safe sex, use of protective hand gloves when handling blood or other body fluids, 
not sharing personal items like nail cutter, clippers, razors, or toothbrushes, single use of only sterilized disposable needles or body 
piercing objects, and screening of pregnant women before child delivery are very significant in HBV prevention.  
Keyword:  Acute Hepatitis B, Chronic Hepatitis B, Risk factors, Symptoms, Transmission, Prevention. 
 
INTRODUCTION 
“Hepatitis” means inflammation of the liver. Hepatitis B is a 
contagious and potentially life threatening liver disease that 
results from infection with a pathogenic agent; the Hepatitis B 
virus. The enveloped DNA virus belongs to the family 
hepadnaviridae [1], its virions are double-stranded particles, 
measuring 40 to 42 nm in diameter [2].  With a genome of only 
3200 base pairs, HBV is one of the smallest DNA viruses 
known. It has an outer lipoprotein envelope that contains three 
related envelope glycoproteins (or surface anti-gens) [3].  
Hepatitis B virus (HBV) infection may develop to: chronic 
hepatitis, hepatic cirrhosis, or primary hepatic cancer. Infection 
with hepatitis B virus (HBV) is a worldwide problem. Over a 
million deaths are recorded annually from chronic HBV 
infection and its complications: cirrhosis or primary liver cancer 
[4]. Liver injury occurs through immune-mediated killing of 
infected liver cells. The body’s immune response tries to get rid 
of the virus by killing the infected cells. It is this self-defence 
mechanism that does most of the damage to the liver over time 
[5]. HBV is a recognized oncogenic virus that confers a higher 
risk of developing Hepatocellular Carcinoma Cancer (HCC) [6].  
Hepatitis B is a disease of significant health importance. Over 
two billion people are known to be infected with Hepatitis B 
virus. Hepatitis B disease is ranked among the ten top killer 
diseases [7].  Ott et al. [8], reported that more than 2 billion 
people alive today have serologic evidence of past or present 
HBV infection, while 250 million are chronically infected and 
are at risk of developing HBV-related liver disease. It was also 
reported that 15-40% of chronically infected patients will 
develop cirrhosis, progressing to liver failure and/or HCC during 
their lifetime [9]. The prevalence of hepatitis B virus infection 
is relatively high in Africa, having the second highest number of 
chronically HBV-infected individuals.  Poynad [10], observed 
that  HBV infection varies epidemiographically with  Africa, 
Asia and the Western Pacific accounting for higher infection 
rates of  ≥ 8%, Southern and Eastern Europe with 2 - 7.9 % 
infection rates, while  Western Europe, North America and 
Australia  infection rates lowest  (< 2 %). The health and 
economic burden of hepatitis diseases in Nigeria is enormous, 
with high mortality. Nigeria is endemic for HBV infection with 
about 18 million known infected people [11].  
Pathogenesis of HBV infection 
Host–virus interaction, mediated by the adaptive immune 
response all together determines the outcome of HBV infection 
[12]. WGO [13], noted that the virus-specific T cell response is 
one of the key factors in the pathogenesis of HBV infection. The 
course and outcome of the disease may be influence viral 
variants. Hollinger and Liang [14], observed that the effect of 
host factors on the progression of disease is not well understood. 
Hepatitis B virus infections rarely become directly cytopathic, 
except in cases of extreme immune suppression [15]. There is 
no age specificity in the infection and development of the 
disease [16].  Acute (self-limiting) infection, fulminant hepatic 
failure, inactive carrier state, and chronic hepatitis with chances 
of progression to cirrhosis and hepatocellular carcinoma are the 
clinical course (but not necessarily sequential) of HBV infection 
[17]. Adults that acquire acute infection usually recover or can 
be managed by supportive therapy, but the chronic type is 
ultimately fatal [18]. The average incubation period of Hepatitis 
B is 60 to 90 days (range is 40 to 160 days)[19].  HBV replicates 
in the hepatocytes of humans and other higher primates but does 
not grow in artificial cell cultures. Kapoor et al.[20], observed 
that in acute hepatitis B, the disease may last from one to six 
weeks but may be prolonged and can be fulminate. The 
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progression from acute to chronic infection is largely influenced 
by the age of the person who comes in contact with the virus. A 
person is said to be chronically infected if the person‘s immune 
system is not able to clear the virus six months later after the 
initial exposure of HBV. NICE [21], explained that the course 
of chronic HBV infection can be divided into the following four 
phases based on markers of replicative or non-replicative 
disease: 
i. the immune tolerant phase 
ii. the immune clearance phase 
iii. the immune control phase and  
iv. immune escape. 
Not all chronic patients experience all phases of persistent 
disease and patients can also move from an immune active to an 
inactive phase and vice versa [22]. 
Transmission of Hepatitis B 
Hepatitis B viral infection is body-fluid borne. The virus can be 
transmitted through vehicles of human transmission, such as 
contact with blood or other body fluids of an infected person.  It 
is spread predominantly by percutaneous or mucosal exposure 
to infected blood and various body fluids, including saliva, 
menstrual, vaginal, and seminal fluids [23]. Transmission occurs 
primarily in two forms: vertical (the passage of pathogens from 
mother to the baby during the period immediately before and 
after birth) or horizontal transmission (the spread of infectious 
agents between members of the same species that are not in a 
parent-child relationship, usually through contact with bodily 
excretions or fluids, such as sputum or blood, semen, and vaginal 
fluids that contain the agents) [24]. Chen and Chang [24], 
enumerated three mechanisms of HBV trans-mission from 
HBsAg-positive mothers to include: (i) trans-placental intra-
uterine transmission; (ii) transmission during delivery by contact 
with maternal infected fluids in the birth canal; and (iii) post 
natal transmission from mothers to infants during child care or 
through breastfeeding. Although it has been observed that HBV 
can infect the fetus in utero, this is not common and is generally 
associated with antepartum haemorrhage and placental tears 
[25]. Beasley et al. [26], observed that the risk of perinatal 
infection is increased if the mother has acute hepatitis B in the 
second or third trimester of pregnancy or within two months of 
delivery. The Hepatitis B virus is 50–100 times more infectious 
than HIV. It is stable on inanimate object for at least 7 days, and 
can be passed through the exchange of body fluids [27].  
Signs and Symptoms of Hepatitis B  
The symptoms of “acute” Hepatitis B viral infection may range 
in severity from a very mild illness with few symptoms or 
asymptomatic, to a serious condition requiring hospitalization 
[28]. Acute Hepatitis B (also refers to as new infection) 
describes the initial stage of the disease, usually within the first 
6 months after acquiring the Hepatitis B virus. Individuals with 
strong body defence mechanism may be able to fight the 
infection and eliminate the virus. However, the infection 
remains and leads to “chronic” or lifelong illness in others [28]. 
Chronic Hepatitis B describes the disease after 6 months of 
infection; the Hepatitis B virus remains in a person’s body, 
causing serious health problems over time. Several cases of 
chronic Hepatitis B are asymptomatic. More than half of the 
patients at this stage are not aware of their Hepatitis B infection 
status. Nevertheless, they still performs the role of reservoir of 
infection; spreading the Hepatitis B virus to others [29]. In acute 
Hepatitis B disease, the symptoms vary significantly, depending 
on the overall health of the infected person.   Bello et al. [29], 
listed the common symptoms of acute Hepatitis B to include: 
fatigue, loss of appetite, nausea, vomiting, fever, headache, 
muscle aches, joint pain, abdominal disturbances, grey-colored 
stool, dark urine and jaundice. Symptoms of acute Hepatitis B 
in adults usually manifest within three months of exposure and 
may persist for weeks or months. 
Risks Factors for Hepatitis B 
CDC [30] reported that any susceptible individual can acquire 
Hepatitis B, but people who are at greater risk, include those who 
engage in any of the following activities, or are characterized 
with any of these: 
i. Have sexual contact with an infected person 
ii. Heterosexual persons with multiple sex partners.  
iii. Have a sexually transmitted disease 
iv. Unvaccinated men who have sex with other men. 
v. Commercial sex workers and those who patronize them  
vi. Inject drugs or share needles, syringes, or other 
injection equipment 
vii. Tattooing; body piercing; and acupuncture. 
viii. Close household contact with an infected person. 
ix. Patient on hemodialysis  
x. Exposed to blood on the job 
xi. Nosocomial exposure 
xii. Use of inadequately sterilized syringes and needles. 
xiii. Intravenous and percutaneous drug abuse 
xiv. Infants born to infected mothers 
xv. Renal dialysis patients 
 
Diagnosis of Hepatitis B 
The three primary markers (or measurable indicators) of HBV 
infection are: 
i. the surface antigen (HBsAg), which indicates current disease 
ii.  total core antibody (HBcAb IgM and IgG), which indicates 
present or past infection; and 
iii.  antibody to the surface antigen (HBsAb), which indicates 
immunity. 
HBsAg-positive specimens are diagnosed further using the 
following secondary markers: 
i. the e antigen (HBeAg), which indicates high viral replication 
and infectivity 
ii.  the e antibody (HBeAb), which indicates low viral 
replication and low-to-moderate infectivity 
iii. the IgM core antibody (HBcIM), which indicates current or 
recent disease. 
        The diagnosis of hepatitis B is done through clinical 
symptoms and laboratory examination. In general, there are 
general considerations in the diagnosis of hepatitis B. A person's 
history, age, risk factors, vaccination status and previous tests 
results should be used to guide appropriate testing. The 
diagnosis of HBV infection is made through blood testing [22]. 
Serological test can be performed on either serum or plasma. 
HBV antigens and antibody are stable at room temperature for 
days, 4°C for months, and frozen at -20°C to -70°C for many 
years. Today, automated enzyme immunoassays that depend on 
colurimetic or chemiluminescence signal measurement, care 
should be taken to avoid haemolysis of the sample as it may 
interfere with the ability of the assay accurately detect these 
markers. Besides, measures should be taken to avoid the 
degradation of the viral nucleic acid in the specimen, which can 
result in falsely low or no measurable viral load. Therefore, 
serum should be removed from the clotted blood within 4 hours 
of collection and stored at -20°C to -70°C [31]. 
      The laboratory diagnosis of acute hepatitis B is made 
through the presence of IgM antibody to HBV core antigen (IgM 
anti-HBc). IgM anti-HBc is rapidly followed by IgG anti-HBc. 
Even though this occurs, IgM may persist for months to years 
and may even reappear during flares of chronic HBV. In self-
limiting cases, there are presence of antibody to the hepatitis B 
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surface antigen (anti-HBs) which indicates recovery from 
infection. This usually appears weeks to months following 
disappearance of serum HBsAg. Markers of HBV replication- 
HBeAg and HBV DNA is also present during the initial phase 
of infection. They are also present in the chronically infected 
individual. HbsAg, HbeAg, and HBV DNA are not specific for 
acute infection [13].    
Significance of viral markers in hepatitis B 
  
Table 1: Significance of viral markers in hepatitis B 
Antigens  
HBsAg  Acute or chronic infection  
HBeAg  Acute hepatitis B  
Persistence implies: continued 
infectious state,  
development of chronicity  
increased severity of disease  
HBV DNA  Implies viral replication  
Found in the serum and liver  
Antibodies  
Anti-HBs  Immunity to HBV; previous 
exposure; vaccination  
Anti-HBe  Seroconversion  
Anti-HBc  
IgM  Acute hepatitis (high titre)  
Chronic hepatitis (low titre)  
IgG  Past exposure to hepatitis B 
(HBsAg-negative)  
Source: WGO [13] 
 
Approved drugs for the treatment for CHB  
List of drugs approved for the treatment of chronic hepatitis B are presented in table 2.  
 
Table 2: Approved drugs for chronic hepatitis B 
Family/drug name                   Status                             Global access: percentage on national 
essential medicines list *  
 
Interferons (IFNs)- immunomodulators 
Activate a host of genes with antiviral, antiproliferative, and immunostimulatory activities 
Interferon alfa-2b FDA approval 1991                      54.0 % 
Peginterferon alfa-2a           FDA   approval 2005                     50.8% 
Peginterferon alfa-2b           FDA   approval 2011                       
Nucleoside/nucleotide analogues (NAs)       
Inhibit the DNA polymerase of HBV and thus HBV replication  
Lamivudine      FDA   approval   1998               66.7% 
Adefovir dipivoxil                 FDA   approval    2002               34.1% 
Entecavir        FDA   approval    2005              34.9 % 
Telbivudine                            FDA   approval    2006               23.8 % 
Tenofovir     FDA    approval   2008               48.4 % 
⃰ Reported percentages of WHO member states with drugs for hepatitis B on their national essential medicines lists or subsidized by 
their governments          
Source:  WGO [13] 
 
REFERENCES 
1. S. Pungpapong, W.R. Kim, and J.J. Poterucha, Natural 
history of hepatitis B viral Infection;   an update for 
clinicians. Mayo Clin Proc.(2007) 82:967-975. 
2. Y. Uyar, C. Cabar, and A. Balci,  Seroprevalence of 
Hepatitis B virus among pregnant women in Northern 
Turkey. Help Monthly (2009) 9:146-149. 
3. N. Hinnachi, S. Hidas, I. Harrabi, S. Mhalla, M. 
Marzouk, H. Ghzel, H. Ghannem, T. Khairi, J. 
Boukadida, Seroprevalence and risk factors for 
hepatitis B Among pregnant women in Central Tunisia. 
Pathol. Biol. (2009) 42:115-120. 
4. Hepatitis B Foundation. Hepatitis B Foundation 
[Internet].(2012). Doylestown, PA. Available from: 
http://www.hepb.org/. Retrieved  on 6th June, 2017 
5. M. Kane, Global programme for control of hepatitis B 
infection. Vaccine (1995): 13(Supp1):47-49 
6. M.J Alter,  "Epidemiology of hepatitis B in Europe and 
worldwide", Journal of Hepatology,  2013 vol. 39, no. 
SUPPL. 1, pp. 64-69.  
7. B.S, Blumberg, Hepatitis B: The Hunt for a Killer 
Virus. Princeton University Press, London. (2002). 264 
-269 
8. J.J, Ott, G.A, Stevens, J. Groeger, S.T. Wiersma,  
Global epidemiology of hepatitis B virus infection: 
new estimates of age-specific HBsAg seroprevalence 
and endemicity. Vaccine (2012):30:2212–2219. 
9. R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. 
Shibuya and V. Aboyans,  Global and regional 
mortality from 235 causes of death for 20 age groups in 
1990 and 2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet (2012). 
380:2095–2108. 
10. T. Poynad, Hepatitis B and C Management and 
Treatment. Booksence Company. (2001). 148  
11. O.O. Ojo and, T. Anibijuwon, Determination of 
antibodies to hepatitis B virus in pregnant women in 
Akure, Ondo state, Nigeria. Cont. J. Microbiol. (2009). 
3:6-10. 
12. E.D Jatau, and A. Yabaya A . Seroprevalence of 
hepatitis B virus in pregnant women attending a clinic 
in Zaria, Nigeria. Sci. World J. (2009).  7-9. 
13. W.G.O. World Gastroenterology Organization Global 
Guideline Hepatitis B. World Gastroenterology 
Organization Press. (2015)  4-17 
14. F. Hollinger, T. Liang, Hepatitis B virus. In: D.M. 
Knipe,P.M. Howley, Fields’ virology. 4th ed. 
  J. of Advancement in Medical and Life Sciences                Volume 6 / Issue 1                         ISSN: 2348-294X   
 
4 
Philadelphia: Lippincott Williams & Wilkins; (2001). 
2971–3036. 
15. R. De Franchis, A. Hadengue, G. Lau, D. Lavanchy, A. 
Lok, and N. McIntyre. EASL International Consensus 
Conference on Hepatitis B. 13–14 September, 2002 
.Geneva, Switzerland. Consensus statement (long 
version). J Hepatol (2003):39 Suppl 1:3–25. 
16. C.L. Ayolabi, M.A. Taiwo, S.A. Omilabu, A.O. 
Abebisi,  and M.A. Fatoba,  Sero-prevalence of 
hepatitis b virus among blood donors in Lagos, Nigeria. 
Afr J Biotechnol, (2006) 5(20):1944-1946. 
17. B.J McMahon, Epidemiology and natural history of 
hepatitis B. Semin Liver Dis (2005):25 Suppl 1:3–8. 
18. C.W. Shepard, E.P. Simard, L. Finelli, A.E. Fiore, Bell 
B.P.  Hepatitis virus infection: Epidemiology and 
vaccination. Epidemiol. Rev. (2006). 28:112-125. 
19. R. Lodha and  S.K Kabra. Hepatitis in India. A review 
of disease epidemiology. india Pediatr (2001) 38:1322-
1325 
20. A. Kapoor, H. Adhen, and S. Kottilil, Strategies to 
eliminate HBV infection. Future Virol (2014) 9 
(6):565-88 
21. NICE. Hepatities B (Chronic) diagnosis and 
management. National Institute for Health and Care 
Excellence. (2013). http.nice.org.uk/guidance/cy165 
22. T.F. Baumert, R. Thimme, and F. Weizsacker. 
Pathogenesis of hepatitis B virus infection. World 
Journal of Gastroenterology. (2007) 13(1): 82-90 
23. E.E. Mast, M.J. Alter, and H.S. Margolis. Strategies to 
prevent and control hepatitis B and C virus infections: 
a global perspective. Vaccine. 1999:17 (13-14):1730–
3. 
24. C. Chen and M. Chang, Hepatitis B and pregnancy; the 
scientific basis for perinatal prevention. Cambridge J. 
Online 21: (2010). 89-113. 
25. D.k. Henderson, L. Dembry, N.O. Fishman, C. Grady, 
T. Lundstrom, and T.N. Palmore, SHEA guideline for 
management of healthcare workers who are infected 
with hepatitis B virus, hepatitis C virus, and/or human 
immunodeficiency virus. Infect Control Hosp 
Epidemiol (2010):31(3):203-32. 
26. R.P. Beasley, L.Y. Hwang, G.C. Lee C.C. Lan, C.H 
Roan, F.Y. Huang, Prevention of perinatally 
transmitted hepatitis B virus infections with hepatitis B 
immune globulin and hepatitis B vaccine. Lancet. 
(1983):2(59):1099–1106. 
27. W. Atkinson, J. Hamborsky, L. McIntyre,  and C.H. 
Wolfe, eds. 2006. Centers for Disease Control and 
Prevention. Epidemiology and Prevention Vaccine – 
Preventable Diseases 9th ed. Washington DC: Public 
Health Foundation.(2006).207-231 
28. O. Ojo, Viral Hepatitis: The Nigerian Picture. The 
National Task-Force on Viral Hepatitis Symposium on 
Liver Cancer and Hepatitis Viruses (1997) Abuja. 9th 
April 1997.  
29. R.M. Bello, E. Obot, H.O.K Olabode. Seroprevalence 
and risk factors associated with Hepatitis B surface 
antigen (HBsAg) amongst patients in Biu, Borno State, 
Nigeria. J Pub Health Epidemiol, (2011) 3(10):448- 
453. 
30. Centers for Disease Control and Prevention CDC. 
Division of Viral Hepatitis (2010) No. 21: 1073 
31. M. Krajden and G. McNabb, Petric M. The Laboratory 
Diagnosis of Hepatitis B virus. Can J. Infect. Dis Med 
Microbiol. (2005) 16 (2): 65-72 
32. Dhf. Hepatitis B. A Vaccine Preventable Diseases. 
Digestive Health Foundation. (2012): 79-83  Mulgrave 
Australia 
33. WHO. Guidelines for the prevention, care and 
treatment of persons with chronic Hepatitis B infection. 
(2015): 112-118.  World Health Organization,  Geneva.
 
Citation: Lord Tertese Angahar. (2017 A Review on Pathogenesis, Transmission, Diagnosis and Prevention of Hepatitis B 
infection. J. of Advancement in Medical and Life Sciences. V6I1. DOI:  10.5281/zenodo.1118144 
 
Copyright: © 2017 Lord Tertese Angahar. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited. 
